Gabapentin Tablet, Film Coated
Product Images NDC 70518-2323

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-2323). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Gabapentin 800mg 70518 2323 01

Gabapentin 800mg 70518 2323 01
Gabapentin is a tablet medication manufactured by Aurobindo Pharma in Hyderabad, India. It comes in a quantity of 90 tablets and should be kept out of reach of children. The source NDC is 65862-0524-05 and the medication has an NDC of 70518-2323-01. The expiration date and lot number are not available. It should be stored between 25°-30°C (59-86°F) and it is only available by prescription. The medication has been repackaged by RemedyRepack Inc. in Indiana, PA.*
FDA Label Image

Gabapentin 800mg 70518 2323 02

Gabapentin 800mg 70518 2323 02
Gabapentin is a tablet medication given by prescription only. It is manufactured in India by Aurobindo Pharma and contains 800 mg of active ingredient. The medication comes in a bottle of 180 tablets and its National Drug Code (NDC) is 70518-2323-02. It is advisable to keep the medication out of reach of children. The medication should be stored at a temperature between 20-25°C (68-77°F) with temperature excursions allowed up to 15-30°C (59-86°F). The lot number and expiration date are not available. The medication has been repackaged by RemedyRepack Inc., Indiana, PA 15701, and the original National Drug Code (NDC) is 65862-0524-05. Directions for use are specified in the package insert.*
FDA Label Image

Gabapentin 800mg 70518 2323 03

Gabapentin 800mg 70518 2323 03
Gabapentin is a medication provided in tablet form with a strength of 800 mg. The National Drug Code (NDC) for this medication is 70518-2323-03. It is manufactured by Aurobindo Pharma in Hyderabad, India and the source NDC is 65862-0524-05. The lot number and expiration date are missing. The quantity provided is 120 tablets. The medication should be kept away from children and stored at a temperature between 25° and 30°C (59-86°F). The package insert contains directions for use. This medication requires an RX and has been repackaged by RemedyRepack Inc.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Gabapentin tablet with a potency of 800mg from the manufacturer Aurobindo Pharma in Hyderabad, India, in a pack of 30 tablets. The National Drug Code (NDC) number is 70518-2323-00, with a source NDC of 65862-0524-05. The tablet package insert should be used to determine dosage direction. The medication should be kept out of children's reach in a storage area kept between 25°C to 30°C (59-86°F). This drug is Rx only, repackaged by RemedyRepack Inc., Indiana, PA 15701, 724.465.8762. There is no expiry date nor LOT number data provided.*
FDA Label Image

Creatinine Clearance (Gabapentin Fig1)

Creatinine Clearance (Gabapentin Fig1)
This text appears to be a formula for calculating Lt (which may stand for something like "renal function" or "glomerular filtration rate") using the patient's age, weight, and creatinine level. However, without more context it is difficult to say exactly what this formula is for or what the resulting value represents.*
FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)
The text describes a Figure 1 showing the weekly mean pain scores in an ITT population study. The study includes a placebo group and a group taking 300mg/day of Gabapentin. There are also names listed such as "Ek Do Tuon Priod" and "Fred Dose Prci" but it is unclear what their significance is.*
FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)
FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)
FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)
This appears to be a graph or chart that is not fully readable without the visual aid. As a result, a description cannot be generated with this limited information.*
FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical Structure (Gabapentin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.